Q4 2024 Management View CEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over £31 billion, with specialty medicines driving performance. Core operating profit ...
Investor's Business Daily on MSN34m
GSK Surges 7% After Bumping Its 2031 Outlook To North Of $50 BillionGSK stock rocketed Wednesday after the pharma titan raised its 2031 sales outlook to north of $50 billion.Please watch the ...
Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...
British pharmaceutical group GSK on Wednesday reported a near halving of net profit in 2024 after settling hefty US lawsuits over its Zantac heartburn drug.
Bernstein analyst Justin Smith maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £23.55. The ...
UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.80. The company’s ...
GSK plans to buy back $2.50 billion in shares and raised its midterm sales target, citing promising pipeline developments.
GSK plans to buy back $2.50 billion in shares and raised its midterm sales target, citing promising pipeline developments. The British pharmaceutical giant said Wednesday that the 2.0 billion-pound ...
GSK’s global performance showed strength across key markets. Sales in the United States reached £16.4 billion, up 6% at ...
Hundreds of thousands of doses of moxidectin – which treats a disease caused by a parasitic worm – are being given to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback